Vor Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VOR research report →
Range $27 – $40
Price Chart
About the company
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials.
- CEO
- Jean-Paul Kress
- IPO
- 2021
- Employees
- 76
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on VOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.04B
- P/E
- 0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -7.91
- EV/EBITDA
- 0.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -830.38%
- ROIC
- -38.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-371,642,000
- Net Income
- $-695,981,000-495.3%
- EPS
- $-70.50-107.4%
- OCF Growth
- -43.2%
- FCF Growth
- -43.8%
- 52W High
- $26.00
- 52W Low
- $6.69
- 50D MA
- $19.55
- 200D MA
- $17.64
- Beta
- 1.83
- RSI (14)
- 49
- Avg Volume
- 931.03K
No earnings-call transcripts are available for VOR yet.
- Free Float
- 65.8%
- Shares Outstanding
- 54.19M
- Float Shares
- 35.67M
of shares held by institutions
105 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 6.76M | ▲ 1.83M |
| Tcg Crossover Management, LLC | 5.67M | 0 |
| Ra Capital Management, L.P. | 4.50M | ▲ 2.10M |
| Fcpm Iii Services B.V. | 3.41M | ▼ 712.08K |
| Blackrock, Inc. | 3.31M | ▼ 161.61K |
| Venrock Adviser, LLC | 3.04M | 0 |
| Frazier Life Sciences Management, L.P. | 2.74M | ▲ 200.00K |
| Vanguard Capital Management LLC | 2.04M | ▼ 48.85K |
| State Street Corp | 1.97M | ▼ 646.53K |
| Caligan Partners LP | 1.93M | 0 |
| Great Point Partners LLC | 1.13M | ▼ 573.09K |
| Millennium Management LLC | 991.53K | ▲ 563.47K |
Held by 210 ETFs
Biggest fund positions in VOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Sokolove Jeremy Brett | other | 1,917 |
| Oct 2, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 500 |
| Oct 2, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 500 |
| Aug 24, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,500 |
| Aug 24, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,500 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 2,100,000 |
| Jul 16, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 213 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 0 |
| Jul 7, 26 | ZACCARDELLI DAVID | other | 42,658 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VOR coverage
Recent articles, reports, and earnings notes.
No research on VOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VOR report →Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
globenewswire.com · Nov 12
Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference
globenewswire.com · Nov 10
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Oct 30
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
reuters.com · Oct 22
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
globenewswire.com · Oct 22
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 5
Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?
defenseworld.net · Oct 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.